CLOV

The global insurtech market is expected to expand from USD 14 billion in 2026 to USD 638 billion by 2035, driven by adoption of AI, cloud computing, blockchain, machine learning, and IoT. Health insurtech leads market share, while North America dominates regionally with Asia expected to achieve higher growth rates. Strategic partnerships between traditional insurers and startups are fueling innovation and scalability.

Clover Health announced that CMS awarded its PPO Medicare Advantage plans a 5-Star rating and HMO plans a 4.5-Star rating for 2027. The company grew Medicare Advantage membership ~48% year-over-year to over 157,000 members. Clover maintained its #1 ranking among non-SNP PPO plans with a HEDIS score of 4.82 out of 5 Stars for the third consecutive year, demonstrating the effectiveness of its Counterpart Assistant platform in supporting physician decision-making.

Clover Health announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J. Miller, M.D. to its Board of Directors, effective immediately. Senator Torricelli will serve on the Audit Committee while Dr. Miller will serve on the Clinical Committee.

The appointments fill two board vacancies and bring the board to nine directors. Both appointees bring extensive experience in healthcare policy, Medicare Advantage, clinical practice, and business strategy.

Clover Health announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J. Miller, M.D., to its Board of Directors, effective immediately. Torricelli will serve on the Audit Committee while Dr. Miller will serve on the Clinical Committee. Both appointments bring complementary expertise in healthcare policy, Medicare Advantage, clinical practice, and business strategy to strengthen the company's governance and execution.